Shandong Xinhua Pharmaceutical Company Limited
000756.SZ · SHZ
Market closed13.69-1.27 (-8.49%)
Key statistics
Previous close14.96
Open14.98
Day high14.98
Day low13.69
52-week high18.70
52-week low11.71
Market cap6.87B
Volume16.16M
Average volume11.54M
P/E ratio37.30
Forward P/E—
EPS0.37
Dividend yield+2.01%
Market context
Why it moved
Shares of 000756.SZ fell sharply today, likely driven by broad sector selling pressure and negative market sentiment weighing heavily on the stock, pushing it to close near its intraday low on elevated volume.
What is happening
Recent company-specific developments and publisher coverage.
富途牛牛 · July 10, 2026Shandong Xinhua Pharmaceutical Company Limited (00719.HK) received an increase of 1.376 million H-shares from E Fund Management Co., Ltd., valued at approximately HK$8.3756 million.marketscreener.com · June 26, 2026Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2025, Payable on 31 July 2026 Mt Newswire · April 15, 2026Shandong Xinhua Pharma Gets China Nod to Register Bumetanide Injection Mt Newswire · March 24, 2026Xinhua Pharmaceutical Gets China Approval for Ibuprofen Pain Relief Granules Mt Newswire · March 4, 2026Xinhua Pharmaceutical Gets Registration Certificate for Two Drugs in China Mt Newswire · February 9, 2026Shandong Xinhua Pharmaceutical Terminates Equity Acquisition Talks With NovoSana Mt Newswire · December 23, 2025Xinhua Pharmaceutical Gets Registration Certificate for Influenza Drug in China Mt Newswire · November 28, 2025Shandong Xinhua Pharmaceutical Gets China Approval for Prednisolone Acetate Raw Material Mt Newswire · November 28, 2025Shandong Xinhua Pharmaceutical Gets China Supplementary Approval for Epinephrine Hydrochloride Injection; Shares Fall 3% Mt Newswire · November 27, 2025Xinhua Pharmaceutical Gets China Nod for Inflammatory Disease Drug-Related Marketing